Key Investor Signals
CTO helped build implant maker acquired by Sorin
Pascal Doguet led technology at Neurotech SA, where implanted vagus nerve stimulators gained two European approvals and one US approval before Sorin acquired the company in 2012.
Founders previously secured reimbursement and 60% market share
Sylvain d'Amico secured French reimbursement for two WallabyPhenox devices. Olivier Ménage led pricing for a Boston Scientific stent launch that reached 60% European market share in six months.
Filed first patent on PTSD neuroinhibition implant
Stimalia filed a patent application covering treatment of PTSD through neuroinhibition, including both the method and the implant designed to dampen stellate-ganglion activity.
Other Positive Signals
- Selected for the imec.istart accelerator's Belgium Autumn 2025 cohort.
- Former Formula One driver Romain Grosjean joined Stimalia as a brand ambassador in July 2026.
Team
Pascal Doguet
CTO and Co-founder
- Led technology at Neurotech SA, where implanted vagus nerve stimulators gained European and US approvals before Sorin acquired the company.
- Co-founded Synergia Medical, built its implanted nerve-stimulation platform from scratch and developed a portfolio of 15 patent families.
- Built Synergia Medical's ISO 13485 quality system for class III implantable medical devices.
Olivier Ménage
CEO and Co-founder
- Co-founded MONA Health, raised a €2.5M seed round and took its retinal-screening product through CE marking under EU MDR.
- Led Man & Science as CEO, secured a Series A and oversaw clinical validation of a miniaturized nerve stimulator for headache.
- Ran European launch pricing for Boston Scientific's TAXUS stent, which reached 60% market share within six months.
Sylvain d'Amico
Co-founder and Chief Clinical Officer
- Led clinical and medical affairs at Symetis, helping raise CHF 23M and securing first-attempt approval for its first-in-human study.
- Secured French reimbursement for WallabyPhenox's two main neurovascular devices as VP of Clinical and Market Access.
- Ran a 60-site, 1,200-patient European coronary-stent study at Boston Scientific after product approval.
Product
Stimalia is developing TraumaTone, a wirelessly powered implant positioned against the stellate ganglion. The device is designed to provide continuous, adjustable neuroinhibition for PTSD through a single outpatient placement, extending the temporary effect of stellate ganglion block into ongoing control.
For patients still symptomatic after therapy
TraumaTone is intended for people who remain symptomatic after cognitive processing therapy or prolonged exposure. It targets physical hyperarousal symptoms such as rapid heartbeat, disrupted sleep and exaggerated startle.
Continuous, adjustable nerve inhibition
Anesthetic blocks fade as the drug clears. TraumaTone is designed to sit on the same nerve target and deliver ongoing, adjustable inhibition; clinicians can set the level or turn therapy off.
Same implant platform for dogs
CalmTone Vet applies the same implant design and stellate-ganglion target to trauma-related behavioral disorders in dogs. The program is covered by the same patent application.
Market Overview
First-line PTSD care includes trauma-focused therapies and two approved antidepressants. Across 36 randomized trials in military and veteran populations, 60% to 72% of patients still met diagnostic criteria after treatment, leaving a substantial group with persistent symptoms today.
Neuromodulation is already an established implant category. The global nerve-stimulation device market was valued at $6.4B in 2025 and is forecast to reach $13.9B by 2033. Inspire Medical Systems, which sells an implanted nerve stimulator for sleep apnoea, generated $912M in 2025 revenue.
About 5% of US adults have PTSD in a given year, equivalent to roughly 13 million people in 2020.
Across 36 randomized trials in military and veteran populations, 60% to 72% still met PTSD criteria after therapy.
Inspire sells an implanted nerve stimulator for sleep apnoea and reported $912M in 2025 revenue.
The global nerve-stimulation device market was $6.4B in 2025 and is forecast to reach $13.9B by 2033
Comparable Outcomes
Axonics
Axonics developed an implanted sacral-neuromodulation system for bladder and bowel disorders. It reached about $366M in revenue in its final full year before acquisition. Boston Scientific completed the acquisition of Axonics in November 2024 for an equity value of approximately $3.7B.
Advanced Neuromodulation Systems
Advanced Neuromodulation Systems developed implanted spinal-cord stimulators for chronic pain and became Medtronic's main independent competitor in the category. St. Jude Medical completed the acquisition of Advanced Neuromodulation Systems in November 2005 for approximately $1.3B.
Interested in More Startups Like Stimalia?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.